Connors Investor Services Inc Eagle Pharmaceuticals, Inc. Transaction History

Connors Investor Services Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 22, 2023	BUY	$15.21 - $22.88 $38,025 - $57,200	2,500 Added 24.84%	12,566 $198,000
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $53,219 - $95,610	3,000 Added 42.46%	10,066 $195,000
Q4 2022 Feb 15, 2023	BUY	$24.98 - $39.77 $176,508 - $281,014	7,066 New	7,066 $206,000
Q2 2022 Aug 16, 2022	SELL	$41.26 - $51.35 $20,630 - $25,675	-500 Reduced 7.61%	6,066 $270,000
Q2 2021 Aug 10, 2021	BUY	$36.86 - $44.5 $242,022 - $292,187	6,566 New	6,566 $281,000
Q1 2021 Sep 15, 2021	SELL	$40.32 - $50.97 $159,909 - $202,147	-3,966 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$41.72 - $51.34 $165,461 - $203,614	3,966 New	3,966 $185,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Connors Investor Services Inc, based on Form 13F filings with the SEC.

Stay updated on Connors Investor Services Inc with notifications on news.